Your Article Summary
See Latest ArticlesRandomized phase 2 study of imc-a12 for her2-expressing advanced breast cancer commences patient enrollment
ImClone Sytems, 11/20/08
ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
BayNews International, 12/02/09